Scroll for more



Online Investor Center

Investor FAQ

When was Sucampo Pharmaceuticals incorporated and in which state?

On December 5, 1996, Sucampo Pharmaceuticals, Inc. was incorporated in the state of Delaware.

Where is Sucampo headquartered?

Sucampo is headquartered at805 King Farm Boulevard, Suite 550, Rockville, Maryland 20850.

When was Sucampo’s initial public offering and at what price?

Sucampo’s initial public offering occurred on August 2, 2007, with 3,750,000 class A common stock shares sold at a price of $11.50 per share.

How many employees does Sucampo have?

As of March 31, 2015, Sucampo employed approximately 84 employees in three continents.

Who is Sucampo’s Transfer Agent?

American Stock Transfer & Trust LLC, 6201 15th Avenue, Brooklyn, NY 11219.


Who is Sucampo’s Independent Auditor?

Ernst & Young, LLP


When does Sucampo’s fiscal year end?

Sucampo runs on a calendar year with the fiscal year ending on December 31.

What is Sucampo’s ticker symbol?

Our class A common stock has been approved for quotation on the NASDAQ Global Market under the symbol “SCMP.”

Does Sucampo pay a dividend?

Sucampo does not currently pay a dividend.

How can I get a copy of Sucampo’s annual report?

A copy of Sucampo’s annual report can be downloaded here.

How can I get more information about Sucampo’s product?

Information about Sucampo’s products is available on our Product page.

How do I obtain additional information about Sucampo?

You can find information on our website about our company, including our Annual Report and latest Corporate Presentation. Please feel free to Contact Us for any additional information. You may also send us a literature request by filling out this form.

Contact Us
Tel: +1-301-961-3400

Sucampo Pharmaceuticals, Inc. is focused on the development and commercialization of specialized medicines that meet major unmet medical needs of patients worldwide. Sucampo has two marketed products – AMITIZA, its lead product, and RESCULA – and a late-stage pipeline of product candidates in clinical development for orphan disease areas. VTS-270 is a mixture of 2-hydroxypropyl-B-cyclodextrins with a specific compositional fingerprint that has been granted orphan designation in the U.S. and Europe and is in a pivotal Phase 2/3 clinical trial for the treatment of Niemann-Pick Disease Type C-1. Sucampo has an option for the North American rights to CPP1- x/sulindac, which is in Phase 3 development for the treatment of familial adenomatous polyposis and has been granted orphan drug designation in the U.S. A global company, Sucampo is headquartered in Rockville, Maryland, and has operations in Japan and Switzerland.